|
|
 |
|
Viewing report
|
|
|
|
Commercial Insight: HIV - From the Na�ve to the Complex
Datamonitor, July 2004, Pages: 184
As HIV therapy reaches a more mature phase, the antiretroviral market is also entering a new cycle.
Companies involved will have to employ new portfolio management strategies to ensure they are optimally positioned to defend against sales erosion.
Product positioning and promotional activity will become increasingly important to the successful launch and sales maintenance of new drugs.
Scope of Report:
The HIV market is analyzed in detail on a country basis (including the US, EU5 and Japan), with historic and forecast sales from 1999 to 2014 provided
An analysis of key top level opportunities and threats for each of the seven markets is provided
A quantification of various key events expected to impact the HIV market and individual drugs is provided, along with a qualitative analysis
Various lifecycle management strategies are analyzed, using case studies, and their applicability for the future is determined
Highlights of Report:
Although expected to witness continued growth to 2014, there will be a number of challenges facing those involved in the HIV market, including generic incursion, the launch of new, second generation products and increasing disease complexity. Companies will have to adopt new strategies to maintain their HIV presence in the face of such challenges.
Although the US will remain the dominant market, accounting for two thirds of total sales, the Japanese market will experience the fastest growth. Alliances with local companies, taking advantage of their domestic knowledge and presence, will enhance the prospects for benefiting from this growth.
Early lifecycle management, such as fixed dose combinations and once-daily reformulation, is recommended to protect against sales erosion from generics and new pipeline products. For some products, establishing a position as the drug of choice in niche markets, such as hepatitis, is a more prudent strategy to ensure maintenance of HIV sales.
Reasons to Purchase Report:
Understand key drivers in the antiretroviral market and predict the future performance of key compounds
Quantify the future size and scope of the HIV market and the potential for new products
Evaluate a range of lifecycle-management strategies to combat the threat of generic incursion and quantify the impact of key patent expiries
Customers who bought this item also bought
Pipeline Insight: HIV - Hold Your Horses
HIV Update 2002 (3) - March
Commercial Insight: HIV in the USA - Increasing Choice, Flexibility and Competition
HIV Update 2001 (3) - The impact of resistance testing
HIV Update 2002 (1) - January
HIV: Future Treatment Directions - A Strategic Analysis of Market Developments and Opportunities
HIV - Benchmarking Rapid Antiretroviral Uptake
HIV Update 2001 (2): Midyear Market Analysis and Forecasts
|
|
|
|
